A Deep Learning Approach for Rapid Mutational Screening in Melanoma
暂无分享,去创建一个
N. Razavian | N. Coudray | T. Sakellaropoulos | M. Snuderl | A. Tsirigos | D. Fenyo | I. Osman | R. Hong | R. Kim | G. Jour | U. Moran | J. Weber | R. Berman | R. Shapiro | Douglas Donnelly | Sofia Nomikou | Ioannis D. Aifantis | Z. Dawood | E. Esteva | A. Hatzimemos | D. Donnelly
[1] E. Neri,et al. Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review , 2020, Diagnostics.
[2] G. Boland,et al. Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors , 2020, Frontiers in Oncology.
[3] Ying Xiao,et al. Combining texture features of whole slide images improves prognostic prediction of recurrence-free survival for cutaneous melanoma patients , 2020, World Journal of Surgical Oncology.
[4] Virtual biopsy using MRI radiomics for prediction of BRAF status in melanoma brain metastasis , 2020, Scientific Reports.
[5] Hyunjin Park,et al. Radiomics Study of Thyroid Ultrasound for Predicting BRAF Mutation in Papillary Thyroid Carcinoma: Preliminary Results , 2020, American Journal of Neuroradiology.
[6] Kyunghwa Han,et al. Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma , 2020, PloS one.
[7] S. Tabbarah,et al. Personalized Breast Cancer Treatments Using Artificial Intelligence in Radiomics and Pathomics. , 2019, Journal of medical imaging and radiation sciences.
[8] Jakob Nikolas Kather,et al. Pan-cancer image-based detection of clinically actionable genetic alterations , 2019, Nature Cancer.
[9] Alexander W. Jung,et al. Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis , 2019, Nature Cancer.
[10] Peiling Tsou,et al. Mapping Driver Mutations to Histopathological Subtypes in Papillary Thyroid Carcinoma: Applying a Deep Convolutional Neural Network , 2019, Journal of clinical medicine.
[11] A. Addeo,et al. The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy , 2019, Front. Med..
[12] D. Power,et al. High concordance of BRAF mutational status in matched primary and metastatic melanoma , 2018, Journal of cutaneous pathology.
[13] A. Spathis,et al. BRAF Mutation Status in Primary, Recurrent, and Metastatic Malignant Melanoma and Its Relation to Histopathological Parameters , 2019, Dermatology practical & conceptual.
[14] James X. Sun,et al. Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy , 2018, OncoTargets and therapy.
[15] N. Razavian,et al. Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning , 2018, Nature Medicine.
[16] Heather D. Couture,et al. Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype , 2018, npj Breast Cancer.
[17] H. Haenssle,et al. Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Linda G. Shapiro,et al. Detection and classification of cancer in whole slide breast histopathology images using deep convolutional networks , 2018, Pattern Recognit..
[19] R. Botella-Estrada,et al. The association between dermoscopic features and BRAF mutational status in cutaneous melanoma: Significance of the blue‐white veil , 2018, Journal of the American Academy of Dermatology.
[20] Toby C. Cornish,et al. US Food and Drug Administration Approval of Whole Slide Imaging for Primary Diagnosis: A Key Milestone Is Reached and New Questions Are Raised. , 2018, Archives of pathology & laboratory medicine.
[21] Kenneth A. Iczkowski,et al. Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer , 2018, International journal of radiation oncology, biology, physics.
[22] Rajarsi R. Gupta,et al. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. , 2018, Cell reports.
[23] Anant Madabhushi,et al. RaPtomics: integrating radiomic and pathomic features for predicting recurrence in early stage lung cancer , 2018, Medical Imaging.
[24] I. Stanganelli,et al. Dermoscopy and confocal microscopy for metachronous multiple melanomas: morphological, clinical, and molecular correlations , 2018, European Journal of Dermatology.
[25] K. Sloth,et al. Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases , 2018, Histopathology.
[26] P. Marcorelles,et al. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma. , 2018, Acta dermato-venereologica.
[27] Mathilde Jalving,et al. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform , 2017, Melanoma research.
[28] Liang Cheng,et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine , 2017, Modern Pathology.
[29] D. Brat,et al. Predicting cancer outcomes from histology and genomics using convolutional networks , 2017, Proceedings of the National Academy of Sciences.
[30] G. Pellacani,et al. BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival. , 2017, Anticancer research.
[31] Ehsan Kazemi,et al. Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images , 2017, bioRxiv.
[32] C. Berking,et al. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care , 2017, BMC Cancer.
[33] Yi Gao,et al. Towards Generation, Management, and Exploration of Combined Radiomics and Pathomics Datasets for Cancer Research , 2017, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.
[34] Martin Wattenberg,et al. SmoothGrad: removing noise by adding noise , 2017, ArXiv.
[35] K. Flaherty,et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.
[36] Sebastian Thrun,et al. Dermatologist-level classification of skin cancer with deep neural networks , 2017, Nature.
[37] A. Ballestrero,et al. Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry , 2016, Oncotarget.
[38] Ce Zhang,et al. Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features , 2016, Nature Communications.
[39] Joel H. Saltz,et al. Automatic histopathology image analysis with CNNs , 2016, 2016 New York Scientific Data Summit (NYSDS).
[40] P. Brousset,et al. Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma. , 2016, Acta dermato-venereologica.
[41] M. Mahalingam,et al. BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin? , 2016, Human pathology.
[42] Jian Sun,et al. Deep Residual Learning for Image Recognition , 2015, 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR).
[43] Jean Claude Zenklusen,et al. A Practical Guide to The Cancer Genome Atlas (TCGA) , 2016, Statistical Genomics.
[44] P. Laurent-Puig,et al. Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France) , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[45] C. Férec,et al. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice. , 2015, Human pathology.
[46] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[47] J. Chipuk,et al. Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas , 2015, Cancer Immunology, Immunotherapy.
[48] S. Rosso,et al. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. , 2015, JAMA oncology.
[49] M. Mihm,et al. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations. , 2015, Human pathology.
[50] Andrew Zisserman,et al. Very Deep Convolutional Networks for Large-Scale Image Recognition , 2014, ICLR.
[51] Michael S. Bernstein,et al. ImageNet Large Scale Visual Recognition Challenge , 2014, International Journal of Computer Vision.
[52] Thomas. Error in Text. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. , 2015, JAMA oncology.
[53] C. Cohen,et al. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. , 2014, Human pathology.
[54] J. Wilmott,et al. Intrapatient Homogeneity of BRAFV600E Expression in Melanoma , 2014, The American journal of surgical pathology.
[55] D. Cappellen,et al. Tumor Homogeneity between Primary and Metastatic Sites for BRAF Status in Metastatic Melanoma Determined by Immunohistochemical and Molecular Testing , 2013, PloS one.
[56] A. von Deimling,et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. , 2013, The Journal of molecular diagnostics : JMD.
[57] R. Ádány,et al. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization , 2012, Melanoma research.
[58] Alessandro Testori,et al. The role of BRAF V600 mutation in melanoma , 2012, Journal of Translational Medicine.
[59] N. Bhatia. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis , 2012 .
[60] K. Flaherty,et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. , 2012, European journal of cancer.
[61] C. Tzen,et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma , 2011, Pigment cell & melanoma research.
[62] H. Zentgraf,et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody , 2011, Acta Neuropathologica.
[63] J. Choi,et al. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.
[64] D. Schadendorf,et al. Genetic and morphologic features for melanoma classification , 2010, Pigment cell & melanoma research.
[65] Li-E. Wang,et al. Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma , 2010, Clinical Cancer Research.
[66] H. Ostrer,et al. Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. , 2009, American journal of translational research.
[67] Jane Fridlyand,et al. Academic Editor: Jonathan Rees, University of Edinburgh, United Kingdom , 2007 .
[68] F. Schmidt. Meta-Analysis , 2008 .
[69] M. Trivett,et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.
[70] Anne E Carpenter,et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.
[71] M. Wood,et al. Analysis and interpretation of data. , 1978, The Journal of family practice.